Down regulation of SPAG9 reduces growth and invasive potential of triple-negative breast cancer cells: possible implications in targeted therapy
Open Access
- 19 September 2013
- journal article
- Published by Springer Science and Business Media LLC in Journal of Experimental & Clinical Cancer Research
- Vol. 32 (1), 69
- https://doi.org/10.1186/1756-9966-32-69
Abstract
Background: Recently, we reported an association of a novel cancer testis (CT) antigen, sperm-associated antigen 9 (SPAG9) expression in breast cancer clinical samples, indicating its potential role in carcinogenesis. Around 15% breast cancers are designated as triple-negative for which treatment modalities are limited. Therefore, in the present study, we assessed the role of SPAG9 in triple-negative breast cancer cells. Methods: SPAG9 mRNA and protein expression was investigated in various breast cancer cells of different hormone receptor status and different subtypes by employing reverse transcriptase-polymerase chain reaction (RT-PCR), real time PCR, Western blotting, indirect immunofluorescence (IIF) and fluorescence activated cell sorting (FACS). Employing plasmid-based small interfering RNA (siRNA) approach, knockdown of SPAG9 was carried out in triple-negative breast cancer cells, MDA-MB-231, to assess its role on various malignant properties in vitro and in vivo. Results: SPAG9 mRNA and protein expression was detected in all breast cancer cells. Further, IIF results showed that SPAG9 was predominantly localized in the cytoplasm of breast cancer cells. FACS analysis revealed distinct SPAG9 surface localization in breast cancer cells. Gene silencing of SPAG9 resulted in significant reduction in cellular proliferation, colony forming ability, migration, invasion and cellular motility of MDA-MB-231 cells. Further, ablation of SPAG9 expression resulted in reduction in the tumor growth of human breast cancer xenograft in nude mice in vivo. Conclusions: In summary, our data indicated that down regulation of SPAG9 reduces growth and invasive potential of triple-negative breast cancer cells, suggesting that SPAG9 may be a potential target for therapeutic use.Keywords
This publication has 24 references indexed in Scilit:
- Cancer testis antigensOncoImmunology, 2012
- Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostatBreast Cancer Research, 2012
- Adenovirus-mediated delivery of CALR and MAGE-A3 inhibits invasion and angiogenesis of glioblastoma cell line U87Journal of Experimental & Clinical Cancer Research, 2012
- Effect of ulinastatin on growth inhibition, apoptosis of breast carcinoma cells is related to a decrease in signal conduction of JNk-2 and NF-κBJournal of Experimental & Clinical Cancer Research, 2012
- OncoImmunology: a new journal at the frontier between oncology and immunologyOncoImmunology, 2012
- Sperm-Associated Antigen 9 Is a Novel Biomarker for Colorectal Cancer and Is Involved in Tumor Growth and TumorigenicityThe American Journal of Pathology, 2011
- Small interfering RNA‐mediated down‐regulation of SPAG9 inhibits cervical tumor growthCancer, 2009
- CT-X antigen expression in human breast cancerProceedings of the National Academy of Sciences of the United States of America, 2009
- Sperm-Associated Antigen 9 Is Associated With Tumor Growth, Migration, and Invasion in Renal Cell CarcinomaCancer Research, 2008
- The Hallmarks of CancerCell, 2000